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features 64 health states for every combination of study/nonstudy eye, and a health 
state representing death, derived from the VIVID/VISTA-DME and RESTORE/REVEAL 
studies. Economic inputs were based on the experts’ opinions.2 The primary and 
secondary endpoints for the study were life years gained and quality-adjusted life 
years (QALY), and years with 1 eye blind, respectively. Incremental cost-effectiveness 
ratios (ICER) were calculated per QALY and years with 1 eye blind. Analyses were 
conducted from the payer perspective and time horizon was lifetime. All costs were 
calculated in Turkish Lira (TL). Results: Total annual costs associated with IVT-AFL 
and ranibizumab were 15,315 and 14,791 TL, respectively. QALYs were 7.343 with 
IVT-AFL and 7.295 ranibizumab. According to the results of the analysis, IVT-AFL 
is a cost effective treatment option when compared with ranibizumab at a cost-
effectiveness threshold of 26,415 TL (calculated threshold from developing country 
defined as 3-fold of annual income per capita, per the World Health Organization). 
The ICER of IVT-AFL versus ranibizumab was 10,866 TL/QALY. Years with 1 eye blind 
were 0.416 with IVT-AFL and 0.647 with ranibizumab, with a difference of 0.231 year 
in favor of IVT-AFL, giving an ICER of 2268 TL/years with 1 eye blind. ConClusions: 
IVT-AFL may be a cost-effective treatment option when compared with ranibizumab 
for treatment of DME in Turkey.
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objeCtives: to assess the cost-effectiveness of twice daily (TD) 10 μ g exenatide 
with insulin glargine (EXE) vs once-daily (QD) liraglutide 1.2 mg or 1.8 mg both 
with insulin detemir (LIRA 1.2 or LIRA 1.8) in patients with type 2 diabetes mellitus 
(T2DM). Methods: the Exenatide Cost-Effectiveness Model, a validated computer 
simulation model, was adapted to the Russian healthcare setting. Patient and inter-
vention effects data were gathered from a clinical trials (Scott et al 2013, Buse et 
al 2011), comparing QD LIRA 1.2 mg, 1.8 mg and EXE 10 μ g TD, as add-on to insulin 
glargine or detemir. The full costs were calculated for 1-st line therapy, based on 
published and local sources (2014). This includes the costs of drug acquisition as well 
as appropriate inpatient, outpatient and primary care management costs (associ-
ated with maintenance and events). In this study we simulated disease progres-
sion and treatment effects per cohort 1,000 patients for 10 years period. Results: 
over a simulation period, treatment with EXE vs LIRA 1.2 drove a mean increase in 
discounted quality-adjusted life expectancy of 0.1 (0.008; 0.015) quality-adjusted 
life years (QALYs), whereas therapy with EXE vs LIRA 1.8 decrease of 0.1 (-0.018; 
-0.011) QALYs. When compared with LIRA 1.2, EXE was the dominant strategy, i.e. 
less costly (-$484) and more effective. When compared to LIRA 1.8, EXE was less 
costly (-$1,500), but less effective. The incremental cost-effectiveness ratio (ICER) 
for LIRA 1.8 vs EXE was estimated at $100,941 per QALY gained, that more greater 
than willingness-to-pay (WTP) threshold for Russia in 2014 $36,373. In this case 
more cost-effective strategy was EXE with insulin glargine. ConClusions: at a 
WTP threshold of $36,373/QALY exenatide is likely to be a cost-effective option for 
the treatment of T2DM in a Russian setting.
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objeCtives: Key challenges in the adequate management of type 2 diabetes include 
maintaining glycemic control whilst minimizing the risk of hypoglycemia, without 
increasing body weight. Glucagon-like peptide-1 (GLP-1) receptor agonists provide 
a multi-factorial approach to treatment, compared with traditional glucocentric 
approaches. The present analysis aimed to compare the cost-effectiveness of GLP-1 
receptor agonists for the treatment of diabetes in the UK. Methods: Changes in 
glycated hemoglobin, blood pressure and body mass index upon initiation of liraglu-
tide 1.2mg, exenatide BID and lixisenatide were taken from a network meta-analysis 
of 13 randomized controlled trials evaluating the efficacy and safety of GLP-1 recep-
tor agonists for the treatment of patients with type 2 diabetes uncontrolled on oral 
antidiabetic drugs. Patient lifetime projections of clinical outcomes and direct costs 
(taken from published UK-specific sources, 2013 GBP) were made in a cohort based 
on the LEAD-6 trial using a published and validated diabetes model. Outcomes 
were discounted at 3.5% annually. Sensitivity analyses were performed. Results: 
Liraglutide was associated with improved quality-adjusted life expectancy versus 
exenatide (9.17 versus 9.16 quality-adjusted life years [QALYs]) and lixisenatide 
(9.17 versus 9.12 QALYs). Improvements were driven by improved glycemic control, 
leading to a reduced incidence of diabetes-related complications. Liraglutide was 
associated with reduced costs versus exenatide (GBP37,520 versus GBP37,607) with 
cost savings as a result of avoided diabetes-related complications entirely offset-
ting increased acquisition costs. Versus lixisenatide, liraglutide was associated with 
increased costs (GBP37,520 versus GBP37,126), driven by increased acquisition costs 
which were partially offset by reduced costs of treatment of complications. Based 
on the projected outcomes, liraglutide was found to be dominant over exenatide 
and associated with an incremental cost-effectiveness ratio of GBP7,367 per QALY 
gained versus lixisenatide. ConClusions: Liraglutide 1.2mg is likely to be con-
sidered cost-effective or cost-saving versus alternative GLP-1 receptor agonists for 
treatment of diabetes in the UK.
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healthcare costs or all-cause medical costs in either sample. ConClusions: This 
real-world study suggests that short-term weight loss is associated with attain-
ment of HbA1c< 7 levels and decreased diabetes-related costs in obese population 
with no prior CVD over subsequent 12 months.
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objeCtives: Type 2 diabetes mellitus (DM) represents an important public health 
issue and it is responsible for a significant epidemiologic and economic burden. A 
cost consequence analysis (CN), aimed at assessing the economic impact of sitaglip-
tin (SITA), compared with sulfonylureas –SU (as second line therapy- add on to met-
formin) was peformed on the basis of the value based pricing approach. Methods: 
A CN of SITA vs SU (glibenclamide5mg) was carried out, on a cohort of 1000 diabetic 
patients, from both the Lombardy Regional Health Service (RHS) and societal per-
spectives by considering 12 and 36 months time horizons. Direct (drug, automonitor-
ing glycemic control, visits, hypoglicaemic- HYPOS- and CV events, and durability 
costs) and indirect costs have been considered. Epidemiologic and effectiveness 
data have been collected through available literature, trials and meta-analyses. 
Economic data have been retrieved through local/regional sources, tariffs and 
from available literature. Results: The CN analysis shows that SITA+metformin 
vs glibenclamide+metformin represents a cost saving alternative, over 3 years 
time horizon, as higher drug costs of SITA are offset by : - lower glycemic control, 
complications and durability costs resulting in a saving of almost € 9.000 from RHS 
perspective - lower productivity loss related to major cardiovascular and to HYPOS, 
leading to a saving of about € 100.000 from societal perspective. Also, SITA vs SU 
would provide, from both perspectives, -236 not severe and -54 severe HYPOS and 
-14 CV events. The analysis performed over 12 months time horizon shows that 
SITA+metformin represents a sustainable alternative from both RHS and societal 
perspectives, by leading to a saving in terms of HYPOS 136 (118 not severe and 18 
severe) and 7 CV events. ConClusions: The analysis performed shows that SITA 
represents a sustainable and cost saving alternative for the management of type 2 
DM from both clinical and economic perspectives in Lombardy.
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objeCtives: Exenatide 2mg once-weekly (EQW) is a glucagon-like peptide-1 
receptor agonist (GLP-1 RA). The objective was to assess the cost-effectiveness 
of EQW compared to the GLP-1 RAs dulaglutide 1.5mg QW, liraglutide 1.2mg 
and 1.8mg once-daily (QD), and lixisenatide 20ug QD for the treatment of adult 
patients with type 2 diabetes mellitus (T2DM) not adequately controlled on met-
formin. Methods: This analysis utilized the Cardiff Model, a previously pub-
lished T2DM disease model. Treatment effects were from a network-meta-analysis. 
Quality-adjusted life years (QALYs) were calculated, with health-state utilities 
applied to weight changes, hypoglycemia, and T2DM-related complications. Costs 
(British pounds, £) included medication and T2DM-related complications. The 
model was run over a 40-year time horizon. Costs and QALYs were discounted at 
3.5% annually. Probabilistic sensitivity analysis (PSA) was performed. Results: 
In all comparisons, EQW was associated with a QALY gain per patient; 0.046 (95% 
confidence interval [CI]: 0.036; 0.056) versus dulaglutide 1.5mg; 0.102 (95% CI: 0.093; 
0.112) versus liraglutide 1.2mg; 0.043 (95% CI: 0.034; 0.053) versus liraglutide 1.8mg; 
and 0.074 (95% CI: 0.064; 0.083) versus lixisenatide 20ug. Cost per patient was lower 
for EQW than for dulaglutide 1.5mg (-£885; 95% CI: -£942; -£827) and liraglutide 
1.8mg (-£2,085; 95% CI: -£2,143; -£2,028). EQW was therefore projected to dominate 
(i.e, lower costs and QALYs gained) dulaglutide 1.5mg and liraglutide 1.8mg. The 
cost difference per patient between EQW and liraglutide 1.2mg and EQW and 
lixisenatide 20ug was £103 (95% CI: £46; £160) and £918 (95% CI: £861; £975), respec-
tively. Cost per QALY gained with EQW versus liraglutide 1.2mg and lixisenatide 
20ug was £1,004 and £12,440, respectively. In the PSA, the probability that EQW 
is cost-effective ranged from 76-99% across all comparisons, at a willingness-to-
pay threshold of £20,000 per QALY gained. ConClusions: Results suggest that 
exenatide 2mg once-weekly is a cost-effective therapeutic option for the treatment 
of T2DM in adults inadequately controlled on metformin alone.
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objeCtives: IVT-AFL is indicated for the treatment of visual impairment due to 
DME. The objective of this analysis was to evaluate the CE of IVT-AFL compared with 
ranibizumab in DME in Turkey. Methods: The CE model is a Markov state transi-
tion model that has 3 separate phases (efficacy, maintenance, rest of life) chosen to 
adequately reflect the typical vision changes in a treated DME patient. The model 
